Abstract: Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.

Abstract: A system for infusing a gas into a vascular access device may include a catheter interface, which may include a distal end, a proximal end, and a lumen extending between the distal end and the proximal end. The system may also include a connector disposed on an outer surface of the catheter interface. The connector may be configured to couple to a reservoir. The reservoir may include a housing, which may include an opening and an impermeable wall. The opening may be configured to couple to the connector of the catheter interface. The reservoir may also include a molecular precursor to a gaseous agent that is suspended in a hydrogel and disposed within the housing. The gaseous agent may be antimicrobial, antithrombogenic, or both antimicrobial and antithrombogenic.

Abstract: Described herein are protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: Intra-oral formulations comprising soft anticholinergic alkyl esters are useful for treating excessive drooling conditions in subjects, such as humans, suffering from sialorrhea. Preferably, at least one soft anticholinergic ester is provided in an effective amount or concentration in an anhydrous intra-oral formulation that can inhibit excessive drooling resulting from a condition known as sialorrhea.

Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.

Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.

Abstract: A hair care composition directed to from about 14% to about 40% of one or more surfactants; from about 0.1% to 10% of one or more surfactant soluble antidandruff agents; wherein when the hair care composition is diluted to 1.3% surfactant concentration has a ratio of surfactant diffusion coefficient to soluble agent diffusion coefficient less than 0.6 or greater than 1.4.

Abstract: Treatment systems, methods, and apparatuses for improving the appearance of skin and other treatments are described. Aspects of the technology are directed to improving the appearance of skin by reducing a vascular structure. A non-invasive cooling device can cover and cool the vascular structure to affect the blood vessels of the vascular structure.

Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol.

Abstract: The invention relates stable compact low viscosity hair care compositions comprising: from about 20 weight % to about 45 weight % total surfactant; from about 2 weight % to about 25 weight % branched anionic surfactant with a tail having an alkyl chain with 12 to 18 carbon atoms; from about 5% weight % to about 30 weight % linear anionic surfactant with a tail having an alkyl chain with 12 to 18 carbon atom; from about 0.1 weight % to about 8 weight % of a viscosity reducing agent; from about 40 weight % to about 80 weight % of water; wherein the concentrated shampoo has Ratio of Linear anionic surfactant to Branched anionic surfactant of about 0.3 to about 5, wherein the concentrated shampoo has a viscosity of less than 3000 cP at 26.5° C.

Abstract: The invention relates to a healthcare product comprising (i) a component selected from the group of heat shock proteins from alfalfa and heat shock protein hydrolysates from alfalfa, the product further comprising imiquimod or a pharmaceutically acceptable salt or derivative thereof. Further, the invention relates to a healthcare product for use in the prophylactic or therapeutic treatment of a skin disorder. Further, the invention relates to HSP for use for use in preventing the occurrence of a negative-side effect of a treatment with imiquimod, or alleviating such side effect.

Abstract: The digital personalized medicine system uses digital data to assess or diagnose symptoms of a subject to provide personalized or more appropriate therapeutic interventions and improved diagnoses. The use of prioritized questions and answers with associated feature importance can be used to assess mental function and allow a subject to be diagnosed with fewer questions, such that diagnosis can be repeated more often and allow the dosage to be adjusted more frequently. Pharmacokinetics of the subject can be estimated based on demographic data and biomarkers or measured, in order to determine a treatment plan for the subject. Also, biomarkers can be used to determine when the patient may be at risk for experiencing undesirable side effects and the treatment plan adjusted accordingly.

Abstract: The present invention provides a novel liquid composition in the form of an emulsion or microemulsion for rectal administration comprising at least one dye, at least one emulsifier, and at least one physiologically acceptable excipient, and its use in a diagnostic endoscopic procedure of sigmoid colon and/or rectum. Preferably, said diagnostic endoscopic procedure of sigmoid colon and/or rectum is an anoscopy, a proctoscopy, a rectoscopy and/or a sigmoidoscopy.

Abstract: This disclosure relates to nucleobase polymers useful for degrading GATA-3 mRNA. In certain embodiments, this disclosure relates to nucleobase polymers and nanoparticles conjugated to nucleobase polymers disclosed herein. In certain embodiments, the nucleobase polymers or nanoparticles can be used in methods of managing disorders associated with excessive GATA-3 expression in inflammatory disorders and respiratory disorders such as asthma.

Abstract: Provided are compositions and methods for treating rosacea and acne. Specifically, a gel or foam composition having a tetracycline antibiotic and uses thereof for treating rosacea and acne are provided.

Abstract: The digital personalized medicine system uses digital data to assess or diagnose symptoms of a subject to provide personalized or more appropriate therapeutic interventions and improved diagnoses. The use of prioritized questions and answers with associated feature importance can be used to assess mental function and allow a subject to be diagnosed with fewer questions, such that diagnosis can be repeated more often and allow the dosage to be adjusted more frequently. Pharmacokinetics of the subject can be estimated based on demographic data and biomarkers or measured, in order to determine a treatment plan for the subject. Also, biomarkers can be used to determine when the patient may be at risk for experiencing undesirable side effects and the treatment plan adjusted accordingly.

Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.

Abstract: A nebulizer utilizing a nozzle assembly includes a main conduit and an air pressure duct. The main conduit is disposed on the nebulizer and has an inner surface and an outer surface. The main conduit has an atomizing opening. The air pressure duct is disposed on one of the inner surface and the outer surface of the main conduit, and has a connecting opening connected to the sensor and a detecting opening that is exposed and adjacent to the atomizing opening. The sensor is disposed inside the nebulizer and determines a pressure change of the atomizing opening by detecting the pressure of the detecting opening. The nebulizer includes an atomizing module and a controlling module electrically connected to the atomizing module and the sensor, and the controlling module determines whether the atomizing module should be turned on based on the pressure change of the atomizing opening detected by the sensor.

Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.

Abstract: The present invention provides diagnostics for identifying and distinguishing various types of lung cancers using serum and/or bronchioalveolar lavage fluid. Signatures of secretory proteins are used to identify and distinguish lung cancers. The biomarker signatures may also be used to separate lung cancers from other inflammatory diseases, monitor progression, or assess treatment efficacy.

Abstract: The present invention belongs, in a general manner to the technological field of the pharmaceutical industry and relates, more specifically, to one or more compositions of second use to be destined for the treatment of melasma. The present invention relates to the use of substances belonging to the group of alpha-adrenergic receptor agonists, in different variable concentrations, for treating conditions of melasma upon human skin. Furthermore, the present invention discloses pharmaceutical compositions, the latter being associated or not with other compounds or methods of treatment, to be utilised for the treatment of melasma.

Abstract: An aqueous, intra-oral, transparent nanoemulsion blend in the form of a stable dispersion is provided that delivers both oil- and water-soluble components of a vitamin supplement in the desired concentrations to the cells of a mammal when orally administered. The transparent nanoemulsion blend includes at least two different bilayer water-core liposome components and at least one monolayer surfactant bound particle component. The transparent nanoemulsion blend optionally may include a micelle formed from phosphatidylcholine (PC).

Abstract: The field of the present invention is that of fosfomycin formulations for parenteral administration, in particular for intravenous administration. Formulations of the prior art provide fosfomycin as a powder to be diluted directly prior to the administration. The aim of the invention is to provide a fosfomycin formulation for parenteral administration which is easier to produce and administer or which lowers the risk of puncture injuries for healthcare professionals and the health risks for the patients (for example due to contamination or incorrect dosages) by preventing additional processing steps. During the course of the invention, it was surprisingly shown that fosfomycin is much more stable in an aqueous solution than what is commonly assumed.

Abstract: A device for detecting and recording animal behavior is provided. The device includes at least one corral that defines a contained field, the base surface of the at least one corral being sensitive to the animal's footprint. The device also includes an image capturing device that cooperates with the base surface to capture a first video frame in which at least one of a tail, body and head of the animal is illuminated by a light below the animal and a second video frame in which both a profile of a full footprint and a profile of a toe print of the animal when the animal is standing on its toes is illuminated by a light that is totally internally reflected within the base surface. A control system is arranged to control the image capturing device to capture the first and second video frames.

Abstract: The present invention pertains to the technological sector of the pharmaceutical industry and, more specifically, refers to a second use composition intended for the treatment of a dermatology condition called Poikiloderma of Civatte. The solution proposed in this document is the use of a topical composition containing any substance alone or in combination from the pharmacological group of alpha-adrenergic receptor agonists in therapeutic quantities to treat color of the lesions of Poikiloderma of Civatte. The application of this composition for the condition of Poikiloderma of Civatte results in significant improvement of the color of the skin lesions, also improving the vascular component present in this condition and can be associated with other compounds.

Abstract: A surgical buttress includes a body portion and a band disposed on each of the distal and proximal ends thereof. The surgical buttress is configured to attach to an end effector of a surgical stapling apparatus. The body portion, having perforations disposed thereon, overlies the working surface of one of the first or second jaws of the end effector. A resilient portion extends transversely beyond the side edges of the first or second jaws. Each band remains attached to the end effector following the firing thereof. The proximal band is removably attachable to a hook feature disposed on one of the first or second jaws of the end effector. The surgical buttress can be made from suitable degradable or non-degradable materials. One embodiment contemplates a detachable and disposable single use loading unit. A method of attaching the surgical buttress to a surgical apparatus is also envisioned.

Abstract: Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group).

Abstract: A method for identifying a dairy animal, the method comprising the steps of: providing an identification system comprising an imaging device and a database of stored vein patterns; obtaining at least one image of at least a portion of an udder of the dairy animal; extracting a vein pattern from the at least one image; comparing the extracted vein pattern to the database of stored vein patterns; and identifying, based on said comparison, the dairy animal in the database of stored vein patterns.

Abstract: The present invention provides a medical aerosol suspension formulation of MDI administration, comprising: a) micronized pa-agonist; b) micronized corticosteroid; c) a sib-therapextric quantity of a moisture-scavenger excipient; and d) a HFA propellant; wherein (a), (b), and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant.

Abstract: The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist.

Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.

Abstract: The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.

Abstract: A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and, optionally, an inhaled corticosteroid, is provided.

Abstract: The present invention addresses the issue of providing an external composition for screen foamers such as pump foamers, that can be safely used even when not removed after application. Provided is an external composition for screen foamers, including a non-ionic surfactant as a foaming component and, ideally, being in a soluble state.

Abstract: An apparatus and method for providing cosmetic treatment to skin comprise one material chemically active in a solid form preferably in a tablet form and a second material which is chemically reactive with the first material so that effervescence is produced during the reaction. The chemically active materials may be activated by a user for providing cosmetic treatment to skin. The activation releases effervescence which urges granules of the reacting materials onto the skin. The size of the granules lowers during the reaction thus providing continuously refining peeling to the skin.

Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.

Abstract: Composition for topical application, for use in increasing the trophism of nasal mucosa, comprising an ester of vitamin E with a carboxylic acid of formula R—COOH, in which R is an alkyl radical having 1 to 19 carbon atoms, or an alkenyl or alkynyl radical having 2 to 19 carbon atoms, and an oily vehicle; such composition can be used for the treatment of chronic atrophic rhinitis and for obtaining tissue repair of the nasal mucosa following nasal and sinus surgery.

Abstract: The present invention relates to melatonin or a pharmaceutically acceptable salt thereof for use as a medicament, the use of melatonin or a pharmaceutically acceptable salt thereof for the preparation of medicament, the use of melatonin as a food supplement and a pharmaceutical unit dosage form.

Abstract: Described are methods for treating a keratinized tissue condition in a subject in need thereof. The method may include providing the subject including the keratinized tissue condition. The method may include conducting one or more treatment cycles on the keratinized tissue. Each treatment cycle may include contacting the keratinized tissue with an acid-activated gas-generating composition. Each treatment cycle may include contacting the keratinized tissue with an acid composition. Each treatment cycle may include allowing the acid composition and the acid-activated gas-generating composition to react effective to generate a gas at the keratinized tissue. The one or more treatment cycles may be effective to at least partly ameliorate the keratinized tissue condition in the subject.

Abstract: The present invention generally relates to a pharmaceutical dosage form and controlled release of biologically active agents, diagnostic agents, reagents, cosmetic agents, and agricultural/insecticide agents. In one embodiment, the dosage form has a substrate that forms a compartment, wherein the substrate includes at least a first piece and a second piece, wherein the first piece operably links to the second piece. The dosage form contains a drug content that is loaded into the compartment. The dosage form also has a releaser operably linked to the substrate which upon contact with water or body fluid is capable of separating the first and second piece to open the compartment and release the drug content.

Abstract: Disclosed herein is an improved marking material, consisting essentially of food quality colorant (such as food coloring), and a carrier (such as water, or vegetable oil or canola oil). A method for using this material for the marking of environmental locations is also disclosed. In one form the material also comprises a propellant, all contained within a pressurized aerosol canister. The aerosol canister embodiment having a valve assembly connected to an actuator and aperture for selectively releasing the marking material. In another form, a pump-style spray bottle is utilized, and in another form a larger fluid container, pump and spray-wand type dispersal unit such as the devices commonly used in lawn and garden care, or equivalent apparatus may be utilized. In these forms, the material may consist of water-based food coloring and/or oil-based food coloring and vegetable oil depending on whether the application is dry surface or snow.

Abstract: A pharmaceutical or cosmetic carrier for topical administration substantially consists of phosphatidylcholine, monoglyceride, fatty acid ester of C1-C3 alcohol; volatile solvent selected from ethanol and its combinations with C3-C4 alcohol and/or volatile silicone oil. Also disclosed are pharmaceutical and cosmetic compositions comprising the carrier and pharmaceutically or cosmetically active agent(s).

Abstract: The present invention relates to compositions and methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.

Abstract: Optically isotropic, thermodynamically and chemically stable microemulsions of antimicrobials comprising of mixtures of N-undecylenoyl glycine, N-capryloyl glycine and 2-phenoxy ethanol for preservation of personal care products are described herein. They offer a broad spectrum of antimicrobial activity by inhibiting the growth of bacteria as well as fungi that can otherwise flourish in personal care products rendering them unsuitable for the use. The personal care products that can be preserved by these microemulsions of antimicrobials are, gels, serums, solutions, lotions, creams, emulsions, wet wipes and the like, containing water in varying amount.

Abstract: A wound healing composition and method for wound healing utilizing a nitrofurazone in a water soluble ointment, activated charcoal, caustic and biebrich scarlet. Applying the composition to the wound and observing epithelial healing along the sides and bottom of the wound. Stopping treatment when the epithelial tissue fills the wound.

Abstract: The invention provides compositions and methods for delivering carbon monoxide (CO) to subjects suffering from inflammatory, cardiovascular, Sickle Cell, and other disease. The compositions are liquids, including Newtonian and non-Newtonian liquids, such as pastes, gels, foams, emulsions, and other non-gaseous compositions, in which CO is dissolved at an amount that, when administered to a patient, provides a therapeutically or prophylactically effective amount of CO to the patient. The compositions can be provided in many forms, including in bottles or cans.

Abstract: The invention relates to an oily composition of a non-steroidal anti-inflammatory agent (NSAIA) for parenteral administration with at least one micronized NSAIA, having an acid function and a biocompatible oily vehicle, such that said NSAIA is in the form of a free acid and said composition does not contain any added liquid agent that can solubilize said NSAIA. The invention also relates to the veterinary use thereof.

Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.